End-to-End Drug Substance Manufacturing for Small Molecules

Abstract

Moving a small molecule from an early synthetic route to reliable commercial supply is rarely a straight scale-up exercise. Route selection, impurity control, process safety, solid-state properties, analytical methods, GMP readiness, and regulatory documentation must develop together. This guide explains how an end-to-end drug substance manufacturing model reduces transfer risk, protects product quality, and helps pharmaceutical teams build a practical path from early development to commercial production. This guide outlines the critical criteria for end-to-end drug substance manufacturing and demonstrates how integrated CDMO platforms—such as Chemexpress—bridge the gap between early-stage route scouting and commercial-scale GMP supply.

Why Drug Substance Manufacturing Problems Rarely Begin in the Plant

A route that works in a medicinal chemistry laboratory is not automatically a manufacturing process. Early routes are usually designed to make material quickly. They may depend on chromatography, dilute reactions, costly reagents, unstable intermediates, or operating conditions that become difficult to control in a larger reactor.

Those compromises are often acceptable during discovery. They become expensive once a program needs toxicology batches, clinical supply, validated analytical methods, or a defensible regulatory package.

The most damaging scale-up problems are rarely caused by reactor size alone. They usually trace back to decisions made earlier: an impractical starting material, an impurity that was never fully characterized, an uncontrolled crystallization, or a reaction hazard discovered too late.

This is why end-to-end drug substance manufacturing should begin with process understanding rather than production capacity. The objective is to create a process that consistently delivers drug substance of the intended quality, at the required scale, with controls that can withstand regulatory review and routine manufacturing.

ICH Q11 describes the same underlying goal: commercial process development should establish a manufacturing process capable of consistently producing drug substance with the intended quality. FDA process validation guidance takes a lifecycle view, linking process design, process qualification, and continued process verification. For development teams, the practical message is clear. Manufacturing readiness is built over time; it cannot be added shortly before an NDA submission.

What End-to-End Drug Substance Manufacturing Should Cover

“End-to-end” is sometimes used too loosely. It should mean more than placing route development, GMP manufacturing, and analytical testing on one service list.

A genuinely integrated model connects the technical decisions made across the entire drug substance lifecycle:

Route scouting and starting-material strategy. Candidate routes are assessed for raw-material availability, intellectual property position, step count, yield, stereochemical control, safety, waste generation, cost, and suitability for scale-up. The selection and justification of regulatory starting materials also need early attention because they affect the content and defensibility of the eventual CTD dossier.

Process development and optimization. Reaction parameters, workups, isolations, and purifications are studied systematically. The development team identifies critical process parameters, establishes acceptable operating ranges, and determines how changes in raw materials or process conditions affect impurity formation and product quality.

Process safety assessment. Exothermic reactions, gas evolution, pressure accumulation, unstable intermediates, dust hazards, and thermal decomposition risks must be evaluated before scale-up. A reaction may appear manageable in a flask but behave very differently when heat and mass transfer become limiting.

Analytical development and impurity control. Methods must be suitable for their intended use, whether that is reaction monitoring, raw-material testing, release testing, stability assessment, or cleaning verification. Process-related impurities, degradation products, residual solvents, elemental impurities, and potentially mutagenic impurities require risk-based control strategies.

Solid-state and particle engineering. Polymorphic form, crystallinity, solvate formation, particle-size distribution, morphology, filtration behavior, drying, and milling can affect process reproducibility and downstream formulation performance. Crystallization should be treated as a designed unit operation, not simply the final step used to isolate the API.

GMP manufacturing and lifecycle supply. Manufacturing capacity must match the program’s current needs without blocking later expansion. Early clinical batches may require only kilograms, while a successful product may eventually need hundreds of kilograms or metric-ton supply.

Technology transfer and regulatory CMC support. Process knowledge has to move with the process. Effective transfer includes development reports, analytical procedures, impurity knowledge, safety data, process risk assessments, specifications, change history, and clear responsibilities between R&D, production, QC, QA, and regulatory teams.

API Process Development: Build for the Next Stage, Not Only the Next Batch

The most useful process-development question is not whether a route can make the next batch, but whether it can support the next stage of development.

During preclinical development, speed still matters, but route decisions should already anticipate later scale-up, GMP execution, and supply requirements.

A practical development program focuses first on the risks most likely to disrupt supply or alter quality. High-throughput experimentation can accelerate solvent, catalyst, base, temperature, and stoichiometry screening. Biocatalysis may replace inefficient chiral resolution or improve selectivity. Flow chemistry can offer better heat and mass transfer for selected hazardous or highly exothermic reactions. Preparative chromatography remains useful for difficult separations, but it should not automatically become the default commercial purification method.

Process robustness matters more than an isolated record yield. A slightly lower-yielding process may be the better manufacturing choice if it provides consistent impurity control, simple isolation, readily available raw materials, and a wider operating range.

The same principle applies to green chemistry. Solvent selection, reaction concentration, atom economy, aqueous waste, catalyst loading, and the number of isolation steps influence both environmental performance and manufacturing economics. These factors are most effectively addressed during route design, before a process becomes locked into clinical and regulatory documentation.

To de-risk complex route development, advanced platforms incorporate high-throughput experimentation (HTE) for rapid condition screening, alongside flow chemistry and photochemistry to safely execute highly exothermic or hazardous reactions that are traditionally difficult to scale in batch reactors.

GMP Drug Substance Manufacturing: Scale Is Only One Part of Readiness

Manufacturing scale is easy to compare. Manufacturing readiness is harder.

A capable small molecule CDMO should be able to explain how equipment fit, containment, cleaning, material flow, analytical release, deviation management, change control, and regulatory documentation will be handled for the specific molecule.

For conventional APIs and advanced intermediates, reactor material of construction, working volume, agitation, temperature range, pressure capability, filtration, drying, and solids handling may determine whether a process can be transferred without major redevelopment. Complex chemistry can add further requirements, including hydrogenation, Grignard chemistry, oxidation, nitration, photochemistry, low-temperature reactions, or high-temperature operations.

Highly potent APIs require another level of control. Occupational exposure limits should drive containment design, operating procedures, environmental monitoring, cleaning strategy, and personal protection. An OEB designation alone is not enough. Sponsors should examine the underlying containment approach and whether the facility has relevant operating experience.

ChemExpress operates dedicated drug substance manufacturing sites for different project profiles. Its Ma’anshan API and intermediate site has approximately 170 reactors ranging from 100 to 8,000 liters, with a reported total reactor volume of about 483,000 liters. Available reaction capabilities include hydrogenation, Grignard chemistry, oxidation, photochemistry, operations down to approximately -80°C, and high-temperature reactions up to approximately 240°C.

A separate Ma’anshan facility supports API, HPAPI, and ADC payload-linker manufacturing.

These are relevant capabilities for oncology and other programs where conventional multipurpose manufacturing controls may not be sufficient.

The Heze site extends capacity for specialty chemicals and intermediates, with about 50 reactors from 500 to 5,000 liters and approximately 115,000 liters of total reactor volume. This capacity supports batch sizes reaching hundreds of kilograms where project and process requirements are suitable.

These figures describe available infrastructure, not an automatic fit for every molecule. Equipment selection, containment category, campaign design, process safety data, waste handling, and regulatory status still need project-specific review.

Keeping Analytical, Solid-State, and Manufacturing Decisions Connected

A fragmented development model often creates avoidable rework. One provider develops the route, another develops the analytical methods, a third performs solid-form screening, and a fourth manufactures the GMP batch. Each handoff can strip away context.

The risk becomes visible when an impurity appears only at scale, a crystallization produces a different polymorph, or a transferred analytical method cannot distinguish a process impurity from the API peak. The manufacturing team then has to reconstruct decisions made months earlier, often under clinical supply pressure.

An integrated team can evaluate these issues together. Process chemists understand where impurities are formed. Analytical scientists determine how to detect and quantify them. Solid-state scientists examine whether changes in solvent, seeding, cooling, agitation, or drying affect physical form. Manufacturing engineers assess equipment fit and scale-dependent behavior. QA and regulatory specialists ensure that decisions are documented consistently.

ChemExpress combines route exploration, process optimization, solid-state research, analytical development, stability studies, technology transfer, GMP manufacturing, and regulatory CMC support within its small molecule platform. Its disclosed solid-state capability spans polymorph screening and characterization, crystallization process development, particle-size work, and commercial manufacturing support. According to the company’s current materials, this team has completed more than 100 solid-state projects.

The wider small molecule platform reports more than 900 delivered projects, including 833 at preclinical or Phase I stages, 116 in Phase II or III, and 17 commercial-stage programs. These figures are useful because they show experience across development transitions, not only isolated laboratory synthesis.

A Scale-Up Case: Redesigning a KRAS Inhibitor Building Block

A disclosed ChemExpress case illustrates why route innovation can matter more than simply increasing batch size.

The project involved a chiral bridged-ring building block used in KRAS inhibitor research: ((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methanol. Published routes presented several manufacturing concerns, including lengthy synthesis, expensive chiral inputs or separation, hazardous operations, and limited suitability for larger-scale production.

ChemExpress developed a four-step diastereoselective route starting from commercially available proline. The strategy used epoxide ring opening followed by base-induced intramolecular alkylation to construct the bridged framework. The process avoided chromatographic purification and delivered the target at greater than 99% ee. Company materials report production above 100 kilograms in a single batch. The route is disclosed in PCT patent application WO2024092420A1.

The value of the case is not the chemistry alone. It shows how starting-material cost, stereochemical control, purification, safety, and batch scale can be addressed as one manufacturing problem. That is the type of route redesign that can change the long-term economics and supply resilience of a small molecule program.

How to Select an End-to-End Small Molecule CDMO

A site visit and a capacity table provide only part of the answer. Sponsors should test how a prospective CDMO thinks.

Ask the team to identify the main scale-up risks in the current route. Review how it would investigate impurity formation and fate. Examine how process safety work is timed relative to scale-up. Confirm whether solid-state scientists, analytical scientists, process chemists, QA, and manufacturing staff work through a shared project structure.

The technology-transfer plan deserves equal attention. A strong plan defines required documents, knowledge gaps, analytical transfer activities, equipment differences, engineering runs, comparability expectations, responsibilities, and decision points. It should also make clear how deviations and process changes will be assessed for regulatory impact.

Supply continuity should be discussed before commercial demand becomes urgent. This includes raw-material sourcing, second-source strategy, manufacturing slot planning, inventory assumptions, storage stability, transportation, business continuity, and the ability to add capacity without changing the registered process unnecessarily.

ChemExpress’s model is designed around this connected workflow, covering RSMs, intermediates, APIs, and HPAPIs from route assessment through GMP manufacturing and CMC support. Its sites provide a broad scale range, while enabling technologies such as high-throughput experimentation, flow chemistry, biocatalysis, photochemistry, preparative chromatography, and solid-state research can be introduced where they solve a defined development problem.

That last point matters. Technology has value when it reduces risk, improves control, or makes a process commercially workable. It should never be added simply because it is available.

FAQ

What is the difference between an API and a drug substance?

In small molecule development, the terms usually refer to the same pharmacologically active chemical substance. “API” remains common in commercial and manufacturing discussions, while “drug substance” is widely used in ICH guidance and CTD regulatory documentation. Drug substance is converted into a drug product through formulation and finished-dose manufacturing.

When is the ideal time to transition a synthetic route to a scalable GMP drug substance process?

Serious scale-up planning should begin before the process becomes locked into repeated clinical manufacture. Preclinical development is often the right time to assess route suitability, starting-material strategy, impurity risks, process safety, solid form, and analytical controls. Not every parameter needs to be commercially optimized at this stage, but major route and supply risks should be understood before larger GMP commitments are made.

What information is required before transferring an API process to a CDMO?

A useful transfer package normally includes the synthetic route, development history, batch records, raw-material specifications, analytical methods, impurity data, process safety information, solid-state knowledge, stability data, critical parameters, known deviations, and the intended clinical or commercial use. Missing information does not always prevent transfer, but it should be identified early and converted into a documented development plan.

Can one manufacturing site handle both conventional APIs and HPAPIs?

Only when the facility has suitable containment, equipment, procedures, and demonstrated operating controls for the required exposure band. HPAPI suitability should be assessed using compound-specific occupational exposure information rather than a general facility label. ChemExpress uses dedicated OEB-5 production lines and negative-pressure isolators for highly potent compounds, while other API and intermediate projects can be assigned to facilities suited to their chemistry, scale, and containment needs.

How does ChemExpress support a drug substance program from development to commercialization?

The small molecule platform covers route scouting, process optimization, process safety, analytical development, impurity control, solid-state research, technology transfer, GMP manufacturing, stability work, and regulatory CMC support. Manufacturing resources range from laboratory and kilogram supply to hundreds-of-kilograms and, where appropriate, larger commercial-scale production. Each project is evaluated against its chemistry, containment, quality, timeline, and regulatory requirements before a manufacturing strategy is proposed.